Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maraviroc - ViiV Healthcare

Next Previous
X
Search
Drug Profile

Maraviroc - ViiV Healthcare

Alternative Names: Celsentri; MVC; Selzentry; UK-427857

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer; University of California at San Francisco
  • Developer International Partnership for Microbicides; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA); Pfizer; ViiV Healthcare
  • Class Antiretrovirals; Cyclohexanes; Small molecules; Triazoles
  • Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • No development reported Hypertriglyceridaemia
  • Discontinued COVID 2019 infections; Rheumatoid arthritis

Most Recent Events

  • 02 Jan 2023 NDR batch#28: QC feedback incorporated; indication discontinued for COVID-2019 infections as per SME feedback; also crosschecked the pipeline
  • 02 Jan 2023 Discontinued - Phase-II for COVID-2019 infections (In the elderly, In adults) in Spain (PO) (NCT04441385)
  • 25 Mar 2022 ViiV Healthcare terminates phase II trial in COVID-2019 infections (In adults, In the elderly) in Spain (PO) (NCT04441385)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top